Key opportunities in the B-cell inhibitors market for non-oncology diseases include the rising demand for targeted immunomodulatory therapies, driven by increasing autoimmune disorder prevalence.

Solid Biosciences Inc. shares dropped more than 8% on Wednesday after the company released data from its Duchenne gene therapy trial. Trading in the stock was briefly halted earlier in the day. The ...

Common supplements like melatonin and magnesium can interact with your prescription drugs. Learn which sleep aids to avoid to stay healthy.

- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified ...

In 1967, Hungarian scientist Endre Mester tried to cure skin cancer in mice using a low-powered ruby laser. He failed to stop ...

In a March 10 update, Leede analyst Douglas Loe maintained a “Speculative Buy” rating and US$16.00 target on Satellos Bioscience ...

Oral TYK2 inhibitor deucravacitinib receives FDA approval for active psoriatic arthritis based on significantly improved ACR20 response rates.

SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex (DAPC) restoration and improvements in ...

Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified ...

REGENXBIO Inc.  today announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202, a potential best-in-class gene therapy for Duchenne muscular dystrophy. Trial ...

Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne Pivotal dose participants exceeded external controls across functional ...